2444308-95-4
2444308-95-4 structure
- Name: Regdanvimab
- Chemical Name: Regdanvimab
- CAS Number: 2444308-95-4
- Molecular Formula:
- Molecular Weight:
- Catalog: Signaling Pathways Anti-infection SARS-CoV
- Create Date: 2023-01-09 08:34:05
- Modify Date: 2024-01-10 12:15:35
-
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19[1].
| Name | Regdanvimab |
|---|
| Description | Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19[1]. |
|---|---|
| Related Catalog | |
| Target |
SARS-CoV-2, ACE2[1] |
| In Vitro | Regdanvimab (CT-P59) (0-1000 ng/mL; 72 h) can neutralize Gamma, Delta and Epsilon variants with IC50s of 161.5-1237 ng/mL[1]. |
| In Vivo | Regdanvimab (CT-P59) (5-80 mg/kg; i.p.; single dose) 可以降低小鼠 Gamma 和 Delta 株的病毒负担[1]。 Animal Model: hACE2 transgenic (TG) mice inoculated with Gamma or Delta variant[1] Dosage: 5, 20, 40, and 80 mg/kg Administration: Intraperitoneal injection, 8 h post-inoculation, single dose Result: Delayed body weight loss and showed a statistically significant difference compared to the placebo group. Prevented the weight loss of the mice infected with Delta variant. Significantly inhibited the virus replication in the respiratory tract. |
| References |
| No Any Chemical & Physical Properties |